Population Pharmacokinetics of an Angiotensin II Receptor Antagonist, Telmisartan, in Healthy Volunteers and Hypertensive Patients

Shinji Tatami, Akiko Sarashina, Norio Yamamura, Takashi Igarashi, Yusuke Tanigawara

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Summary: Objective: To describe the factors affecting pharmacokinetics of telmisartan, an angiotensin IIreceptor antagonist, a population pharmacokinetic (PPK) model has been developed based upon the data collected from healthy volunteers and hypertensive patients. Methods: A total of 1566 plasma samples were collected from 20 healthy volunteers and 129 hypertensive patients, together with the demographic background. The data were analyzed by the NONMEM program using two-compartment model with first-order absorption. The robustness of the obtained PPK model was validated by the bootstrapping resampling method. Results: The oral clearance (CL/F) was found to be associated with age, dose and alcohol consumption, but neither related to serum creatinine nor smoking history. The volume of distribution for the central compartment was related to age and dose, and the volume of distribution for the peripheral compartment was related to body weight and gender. The absorption rate constant (Ka) and the absorption lag time were described as function of close. The CL/F decreased with advanced age. The CL/F decreased and Ka increased with higher dose, reflecting the super-proportional increase in the plasma levels of telmisartan. The AUC and Cmaxvalues predicted by the present PPK model were well consistent with the observed values. The means of parameter estimates obtained with 200 bootstrap replicates were within 95-111% of the final parameter estimates from the original data set. Conclusion: A PPK model for telmisartan developed here well described the individual variability and exposure, and robustness of the model has been validated by the bootstrapping method.

Original languageEnglish
Pages (from-to)203-211
Number of pages9
JournalDrug Metabolism and Pharmacokinetics
Volume18
Issue number3
DOIs
Publication statusPublished - 2003 Feb 1

Fingerprint

Angiotensin Receptor Antagonists
Healthy Volunteers
Pharmacokinetics
Population
Angiotensins
Alcohol Drinking
Area Under Curve
Creatinine
Smoking
History
Body Weight
Demography
telmisartan
Serum

Keywords

  • covariate
  • model validation
  • modeling
  • NONMEM
  • population pharmacokinetics
  • telmisartan

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Population Pharmacokinetics of an Angiotensin II Receptor Antagonist, Telmisartan, in Healthy Volunteers and Hypertensive Patients. / Tatami, Shinji; Sarashina, Akiko; Yamamura, Norio; Igarashi, Takashi; Tanigawara, Yusuke.

In: Drug Metabolism and Pharmacokinetics, Vol. 18, No. 3, 01.02.2003, p. 203-211.

Research output: Contribution to journalArticle

@article{384a9e679d5a43c0b9adfebcb9a3d20a,
title = "Population Pharmacokinetics of an Angiotensin II Receptor Antagonist, Telmisartan, in Healthy Volunteers and Hypertensive Patients",
abstract = "Summary: Objective: To describe the factors affecting pharmacokinetics of telmisartan, an angiotensin IIreceptor antagonist, a population pharmacokinetic (PPK) model has been developed based upon the data collected from healthy volunteers and hypertensive patients. Methods: A total of 1566 plasma samples were collected from 20 healthy volunteers and 129 hypertensive patients, together with the demographic background. The data were analyzed by the NONMEM program using two-compartment model with first-order absorption. The robustness of the obtained PPK model was validated by the bootstrapping resampling method. Results: The oral clearance (CL/F) was found to be associated with age, dose and alcohol consumption, but neither related to serum creatinine nor smoking history. The volume of distribution for the central compartment was related to age and dose, and the volume of distribution for the peripheral compartment was related to body weight and gender. The absorption rate constant (Ka) and the absorption lag time were described as function of close. The CL/F decreased with advanced age. The CL/F decreased and Ka increased with higher dose, reflecting the super-proportional increase in the plasma levels of telmisartan. The AUC and Cmaxvalues predicted by the present PPK model were well consistent with the observed values. The means of parameter estimates obtained with 200 bootstrap replicates were within 95-111{\%} of the final parameter estimates from the original data set. Conclusion: A PPK model for telmisartan developed here well described the individual variability and exposure, and robustness of the model has been validated by the bootstrapping method.",
keywords = "covariate, model validation, modeling, NONMEM, population pharmacokinetics, telmisartan",
author = "Shinji Tatami and Akiko Sarashina and Norio Yamamura and Takashi Igarashi and Yusuke Tanigawara",
year = "2003",
month = "2",
day = "1",
doi = "10.2133/dmpk.18.203",
language = "English",
volume = "18",
pages = "203--211",
journal = "Drug Metabolism and Pharmacokinetics",
issn = "1347-4367",
publisher = "Japanese Society for the Study of Xenobiotics",
number = "3",

}

TY - JOUR

T1 - Population Pharmacokinetics of an Angiotensin II Receptor Antagonist, Telmisartan, in Healthy Volunteers and Hypertensive Patients

AU - Tatami, Shinji

AU - Sarashina, Akiko

AU - Yamamura, Norio

AU - Igarashi, Takashi

AU - Tanigawara, Yusuke

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Summary: Objective: To describe the factors affecting pharmacokinetics of telmisartan, an angiotensin IIreceptor antagonist, a population pharmacokinetic (PPK) model has been developed based upon the data collected from healthy volunteers and hypertensive patients. Methods: A total of 1566 plasma samples were collected from 20 healthy volunteers and 129 hypertensive patients, together with the demographic background. The data were analyzed by the NONMEM program using two-compartment model with first-order absorption. The robustness of the obtained PPK model was validated by the bootstrapping resampling method. Results: The oral clearance (CL/F) was found to be associated with age, dose and alcohol consumption, but neither related to serum creatinine nor smoking history. The volume of distribution for the central compartment was related to age and dose, and the volume of distribution for the peripheral compartment was related to body weight and gender. The absorption rate constant (Ka) and the absorption lag time were described as function of close. The CL/F decreased with advanced age. The CL/F decreased and Ka increased with higher dose, reflecting the super-proportional increase in the plasma levels of telmisartan. The AUC and Cmaxvalues predicted by the present PPK model were well consistent with the observed values. The means of parameter estimates obtained with 200 bootstrap replicates were within 95-111% of the final parameter estimates from the original data set. Conclusion: A PPK model for telmisartan developed here well described the individual variability and exposure, and robustness of the model has been validated by the bootstrapping method.

AB - Summary: Objective: To describe the factors affecting pharmacokinetics of telmisartan, an angiotensin IIreceptor antagonist, a population pharmacokinetic (PPK) model has been developed based upon the data collected from healthy volunteers and hypertensive patients. Methods: A total of 1566 plasma samples were collected from 20 healthy volunteers and 129 hypertensive patients, together with the demographic background. The data were analyzed by the NONMEM program using two-compartment model with first-order absorption. The robustness of the obtained PPK model was validated by the bootstrapping resampling method. Results: The oral clearance (CL/F) was found to be associated with age, dose and alcohol consumption, but neither related to serum creatinine nor smoking history. The volume of distribution for the central compartment was related to age and dose, and the volume of distribution for the peripheral compartment was related to body weight and gender. The absorption rate constant (Ka) and the absorption lag time were described as function of close. The CL/F decreased with advanced age. The CL/F decreased and Ka increased with higher dose, reflecting the super-proportional increase in the plasma levels of telmisartan. The AUC and Cmaxvalues predicted by the present PPK model were well consistent with the observed values. The means of parameter estimates obtained with 200 bootstrap replicates were within 95-111% of the final parameter estimates from the original data set. Conclusion: A PPK model for telmisartan developed here well described the individual variability and exposure, and robustness of the model has been validated by the bootstrapping method.

KW - covariate

KW - model validation

KW - modeling

KW - NONMEM

KW - population pharmacokinetics

KW - telmisartan

UR - http://www.scopus.com/inward/record.url?scp=85009545147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009545147&partnerID=8YFLogxK

U2 - 10.2133/dmpk.18.203

DO - 10.2133/dmpk.18.203

M3 - Article

VL - 18

SP - 203

EP - 211

JO - Drug Metabolism and Pharmacokinetics

JF - Drug Metabolism and Pharmacokinetics

SN - 1347-4367

IS - 3

ER -